Reported 7 months ago
PharmaEssen (6446) announced on June 11, 2024, that its new drug Ropeg for treating polycythemia vera (PV) has obtained drug certification from Malaysia's National Pharmaceutical Regulatory Agency, marking its second entry into the ASEAN market after Singapore. PV is a type of myeloproliferative neoplasm (MPN) disease, with an estimated 1,000 PV patients in Malaysia. Ropeg, a new generation of long-acting interferon independently developed by PharmaEssen, has been approved for PV treatment in approximately 40 countries globally, including major markets like the EU, US, and Japan, with a growing number of patients using the medication. PharmaEssen saw increased sales in the US market thanks to the rare blood cancer drug Ropeg, achieving a record-breaking self-reported revenue of 790 million NTD in May, up by 18.46% monthly and 89.03% annually. The company also obtained drug certifications in Singapore at the end of May and in Malaysia in June, with expectations of securing certification in China by the end of the year. Additionally, Taiwan Index Company announced the inclusion of PharmaEssen in the Taiwan Mid-Cap 100 Index and Taiwan Developed Index, effective after market close on June 21. Taiwanese investors show a preference for MeiSco Biomedical among the top five stocks, and a new Japanese investment cooperation platform for derivative products will be launched next year.
Source: YAHOO